OpenEvidence could be open to a sale after $15 billion round, Business Insider reported
- Place in VP50
- #27
- Sources
- 2
- Claims verified
- 4 of 6
What happened
Business Insider reported on September 24, 2026 that OpenEvidence, the medical AI startup it called the "ChatGPT for doctors," was valued at $15 billion in a new funding round. According to the report, a person familiar with the matter said OpenEvidence could be open to selling itself, with access to computing part of the appeal. The person tied that to computing becoming scarcer if anti-AI sentiment curbs data center expansion. Business Insider said it could not verify acquisition interest from possible buyers and that the company may prefer to remain independent.
AI Weekly, which summarized the report, said the round was $250 million and that the valuation was 25% above the $12 billion set in a January 2026 Series D. It described OpenEvidence as an AI clinical search engine used by roughly 40% of US physicians. Citing unnamed sources, it said the founders were fielding acquisition interest and could be open to selling the company rather than pursuing an IPO. Neither source named a buyer, a price or terms, and no sale was announced.
Key points
- Business Insider reported OpenEvidence was valued at $15 billion in a new funding round.12
- A person familiar said OpenEvidence could be open to selling itself, with computing access part of the appeal.1
- Business Insider said it could not verify buyer interest and that the company may prefer to stay independent.1
- AI Weekly gave the round as $250 million, 25% above a $12 billion January 2026 Series D mark.2
- No buyer, price or terms were named in either source.12
Why it matters
The report points to a sale as a possible exit route besides an IPO. It rests on unnamed sources, and Business Insider said it could not verify buyer interest.
AI Weekly put the $15 billion valuation 25% above the $12 billion set in January 2026. That is a higher reference price for any sale of existing shares, though the round details come from a secondary summary.
The person familiar named access to computing as part of the appeal of a sale and said computing could become scarcer if anti-AI sentiment curbs data center expansion. That frames compute capacity as part of the business a buyer would weigh.
In context
| Round | Date | Post-money valuation | Raised | Led by |
|---|---|---|---|---|
| Series A | Feb 19, 2025 | $1.0B | $75M | Sequoia Capital |
| Series B | Jul 15, 2025 | $3.5B | $210M | Google Ventures and Kleiner Perkins |
| Series C | Oct 20, 2025 | $6.0B | $200M | GV |
| Series D | Jan 21, 2026 | $12B | $250M | DST Global and Thrive Capital |
| Funding round | Sep 2026 | $15B | $250M | Andreessen Horowitz |
Updated
Fact-check
- OpenEvidence was valued at $15 billion in a new funding round, reported September 24, 2026.Confirmed by [2] AI Weekly (September 24, 2026), which gives the $15 billion valuation; the [1] Business Insider headline in our event data says the same. The Business Insider page was blocked for me.Verified
- The round was $250 million, 25% above the $12 billion valuation set in a January 2026 Series D.Confirmed by [2] AI Weekly, a summary of the Business Insider report.Verified
- OpenEvidence could be open to selling itself, with founders fielding acquisition interest, rather than pursuing an IPO.Confirmed by [2] AI Weekly, which attributes it to unnamed sources and says the company could be open to selling rather than pushing on to IPO.Verified
- Access to computing was part of the appeal, tied to computing becoming scarcer if anti-AI sentiment curbs data center expansion.Rests on the writer's read of [1] Business Insider, which was blocked for me; [2] AI Weekly does not mention computing.Partly verified
- Business Insider could not verify acquisition interest and said the company may prefer to remain independent.Rests on the writer's read of [1] Business Insider, which was blocked for me; [2] AI Weekly carries no such caveat.Partly verified
- OpenEvidence is used by roughly 40% of US physicians.Confirmed by [2] AI Weekly, which calls it an AI clinical search engine used by roughly 40% of US physicians.Verified
Sources
- [1]Business Insider (opens in a new tab)The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding roundOpenEvidence could be open to selling itself, which includes access to computing
- [2]AI Weekly (opens in a new tab)OpenEvidence Raises $250M at $15B, 25% Above January's $12B Mark and Weighing Salecould be open to selling the company rather than pushing on to IPO
